Browse the evidence

Psychosocial factors (confidence, social support, emotional eating) and metabolic status are stronger predictors of weight loss success in behavioral obesity treatment than diet type (low-fat vs. low-carb) or demographic variables alone.

If you are starting a weight loss program, your success is less about whether you choose low-fat or low-carb and more about your mindset and environment. Assess your confidence in sticking to the plan, manage emotional eating, and ensure your social circle is supportive. If you struggle with emotional eating, seek specific psychological support alongside dietary changes.

Tirzepatide treatment significantly reduces food cravings and preferences for energy-dense foods (high fat, high sugar, fast food fats) in people with obesity, independent of caloric restriction.

If you struggle with intense cravings for high-fat or high-sugar foods, tirzepatide can help reduce these urges. This isn't just about willpower; the medication physiologically lowers the 'pull' of these foods, making it easier to stick to a healthy diet.

Tirzepatide specifically reduces cravings for fast-food fats (e.g., pizza, hamburgers) more than other high-fat foods (e.g., sausage, fried fish).

Tirzepatide may be particularly effective at reducing cravings for specific fast-food items like pizza and burgers compared to other high-fat foods.

GLP-1 receptor agonist (GLP-1RA) treatment in obese individuals causes a modest absolute decrease in skeletal muscle mass, but preserves or improves relative muscle mass and strength, resulting in maintained or enhanced physical performance.

If you are taking GLP-1 medications for weight loss, expect a small, normal amount of muscle loss alongside your fat loss. This is not pathological wasting; your muscles are actually working better relative to your new body weight. Focus on maintaining strength through activity, as your mobility and endurance may actually improve.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists are indicated for patients with type 2 diabetes who are inadequately controlled on oral antihyperglycemic drugs (OADs) with an HbA1c less than 10% and within 2% of their glycemic goal, or for those already on basal insulin who remain above goal.

If you are taking oral diabetes medications but your blood sugar is still too high (HbA1c less than 10% and within 2% of your target), or if you are already on basal insulin but your levels are still above goal, ask your doctor about a fixed-ratio combination (FRC). These are single injections that combine a long-acting insulin with a GLP-1 medication. They are designed to lower blood sugar effectively, minimize weight gain, and reduce the number of injections you need to manage compared to traditional basal-bolus therapy.

For patients with Type 2 Diabetes requiring basal insulin, a glycated hemoglobin (HbA1c) goal of less than 7% is appropriate, whereas a goal of less than 6.5% is less likely to be appropriate due to increased risks of hypoglycemia and weight gain.

If you are on basal insulin, aim for an HbA1c of less than 7%. Trying to get it below 6.5% when you are on insulin can increase your risk of dangerous low blood sugar and weight gain without providing significant additional long-term benefits. Your doctor should adjust your goal based on your specific health situation, but <7% is generally the safe target for insulin users.

Incretin receptor activators (GLP-1RA and GIP/GLP-1 dual agonists) cause a reduction in skeletal muscle mass (SMM) that is proportional to fat loss, with approximately 5% of lean body mass lost for every 10% reduction in total body weight, potentially leading to sarcopenia in a subset of treated patients.

If you are taking GLP-1RA or similar weight-loss medications, be aware that you will lose some muscle along with fat. To minimize this, engage in structured exercise programs and discuss monitoring your muscle mass with your doctor, especially if you are older or have existing frailty.

The ratio of serum creatinine to cystatin C (Sarcopenia Index, SI) is a valid, non-invasive biomarker for estimating skeletal muscle mass and predicting mortality in sarcopenic populations, including those treated with GLP-1RA.

Ask your doctor about using a Sarcopenia Index (SI), calculated from your routine creatinine and cystatin C blood tests, to monitor your muscle health while on weight-loss medications. This simple calculation can help detect muscle loss early.

Orforglipron significantly improves lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol, independent of weight loss magnitude.

Orforglipron not only helps with weight loss but also significantly improves heart health markers. It lowers bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). These improvements occur alongside weight loss and contribute to a lower risk of cardiovascular disease, making it a comprehensive treatment for obesity-related metabolic risks.

Treatment with extended-release naltrexone/bupropion (NB) produces weight loss that is disproportionately derived from fat mass rather than lean mass compared to placebo, resulting in a favorable shift in the lean-to-fat mass ratio.

If you are using naltrexone/bupropion for weight loss, the medication helps you lose more fat and preserve more muscle than dieting alone. This is beneficial for long-term metabolic health. Ensure you are following a caloric deficit and staying active as instructed.

Monogenic obesity caused by leptin deficiency can be effectively treated with recombinant leptin therapy, restoring normal appetite regulation.

This intervention is not for the general population. It applies only to a tiny fraction of individuals with confirmed monogenic leptin deficiency. Standard weight loss strategies remain the primary approach for >99% of cases.

Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.

Obesity medications are not a temporary fix but a long-term management tool for a chronic disease. They work by resetting your body's biological 'thermostat' to a lower weight. If you stop taking them, your biology will fight to regain the weight. Therefore, these medications should be viewed as lifelong treatments, similar to blood pressure medication, to maintain your health.

Metabolic adaptation during weight loss involves a 15-20% reduction in daily energy expenditure beyond what is expected from mass loss, which persists until the previous weight is regained.

When you lose weight through dieting, your body burns 15-20% fewer calories than expected for your new size. This 'metabolic adaptation' does not go away over time; it stays until you regain the weight. This is why maintaining weight loss through diet alone is so difficult—you must eat significantly less than a healthy person of your new weight would.

GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.

If you have BED or BN, GLP-1RAs like semaglutide or liraglutide can significantly reduce binge eating episodes by changing how your brain responds to food rewards and increasing fullness. This is supported by systematic reviews, though it is not a standalone cure and should be monitored by a clinician, especially given potential gastrointestinal side effects.

GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.

Standard body composition metrics (DXA) overestimate muscle loss in obesity because they misclassify visceral and subcutaneous fat as 'lean body mass'; MRI-based 'adipose tissue-free muscle volume' provides a more accurate assessment of true muscle mass.

If you are using DXA scans to track muscle loss on GLP-1s, be aware that these machines often mistake visceral fat for muscle. This can make it look like you are losing more muscle than you actually are. Focus on functional strength (grip, lifting) rather than just the DXA number.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to either component alone, but are limited by a low GLP-1RA dose relative to the insulin dose, making separate dosing preferable for obese patients requiring higher GLP-1RA doses.

Fixed-ratio combinations (like IDegLira, iGlarLixi, or IcoSema) are effective for lowering blood sugar and weight compared to using just insulin or just a GLP-1 drug. However, because the ratio of insulin to GLP-1 drug is fixed, these combinations often deliver too little GLP-1 drug for obese patients who need higher doses for maximum weight loss and glucose control. If you are obese or need high doses of GLP-1RA, separate injections of basal insulin and GLP-1RA allow you to titrate each drug independently to your optimal dose.

Roux-en-Y gastric bypass (RYGB) and Health Behavior Intervention (HBI) are cost-effective strategies for managing class III obesity, whereas current-price pharmacotherapies (semaglutide and tirzepatide) are not cost-effective compared to no treatment or HBI.

For individuals with class III obesity, Roux-en-Y gastric bypass offers the best long-term health outcomes and cost-effectiveness. Health Behavior Intervention (13 counseling sessions) is also cost-effective. Current GLP-1/GIP medications are not cost-effective at current prices, though lower prices could change this.

Antiobesity medications (AOMs) improve cardiovascular outcomes, hypertension, and metabolic liver disease in older adults, but their use requires caution due to an increased risk of sarcopenia.

For older adults, AOMs are a powerful tool to treat obesity-related health issues like heart disease and diabetes. However, because losing weight can also lead to muscle loss (sarcopenia), these medications should be used cautiously and monitored closely by a doctor, often alongside lifestyle changes.

The presence of obesity-related complications (e.g., Type 2 Diabetes, Hypertension) significantly amplifies medical costs, with costs up to 5.2 times higher for those with multiple complications compared to obesity alone.

Having obesity-related complications like Type 2 Diabetes or Hypertension drastically increases medical costs (up to 5.2x). This underscores the importance of not just losing weight, but also managing these specific conditions to control overall healthcare spending.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity (measured by AHI) and improves cardiometabolic risk factors in patients with obesity and moderate-to-severe OSA.

If you have obesity and moderate-to-severe sleep apnea, Tirzepatide is a newly approved medication that can significantly reduce the severity of your apnea (AHI) and improve blood pressure and inflammation. It works primarily by promoting weight loss and potentially affecting brain pathways related to breathing control. Because stopping the drug leads to weight regain, it is likely a long-term treatment. It is not a substitute for PAP therapy in all cases, but it is a powerful new tool, especially for those who struggle with CPAP adherence.

Combining CPAP with weight loss (via pharmacotherapy or lifestyle) yields greater improvements in cardiovascular risk profiles (specifically systolic blood pressure) than either treatment alone.

If you use CPAP for sleep apnea, adding weight loss (through diet, exercise, or medications like Tirzepatide) provides extra protection for your heart and blood pressure that CPAP alone does not offer. The combination is superior to either treatment by itself.

Resistance training does not reduce flexibility; this is a common myth.

You do not need to fear that lifting weights will make you stiff. Resistance training, when performed through a full range of motion, does not reduce flexibility and can be part of a balanced fitness routine.

Low-load, high-volume resistance training is as effective as high-load resistance training for maximizing strength.

If your goal is to get stronger (maximal strength), you need to lift heavier loads. Lighter weights with high repetitions are not as effective for this specific goal.